Description
Description:
Revolade is a brand name for a medication manufactured by GlaxoSmithKline (GSK) Pharmaceuticals Ltd. Each tablet contains 25 mg of the active ingredient Eltrombopag. It is used in the treatment of various conditions related to low platelet counts, such as thrombocytopenia.
Active Ingredient:
Eltrombopag is the active ingredient in Revolade. It belongs to a class of medications known as thrombopoietin receptor agonists. Eltrombopag works by stimulating the production of platelets in the bone marrow, thereby increasing platelet counts in the blood.
Indications:
Revolade is indicated for the treatment of thrombocytopenia, which is characterized by low platelet counts. It may be prescribed for patients with conditions such as immune thrombocytopenia (ITP), chronic hepatitis C-associated thrombocytopenia, and aplastic anemia.
Dosage and Administration:
The dosage of Revolade may vary depending on the individual’s medical condition, platelet count, and response to treatment. It is typically taken orally once daily, with or without food. The recommended starting dose for most indications is 25 mg once daily, with adjustments made based on platelet counts and tolerability.
Precautions:
Before taking Revolade, patients should inform their healthcare provider about any pre-existing medical conditions, allergies, or medications they are taking. Regular monitoring of platelet counts and liver function may be required during treatment. Revolade should not be used in patients with certain liver conditions or a history of blood clots.
Side Effects:
Common side effects of Revolade may include headache, nausea, diarrhea, fatigue, and muscle pain. In some cases, more serious side effects such as liver problems, thrombosis (blood clots), or cataracts may occur. Patients should seek medical attention if they experience any unusual symptoms or side effects while taking Revolade.
Conclusion:
Revolade, containing the active ingredient Eltrombopag, is a medication used for the treatment of thrombocytopenia associated with various conditions. Manufactured by GlaxoSmithKline (GSK) Pharmaceuticals Ltd., Revolade is available in tablet form, with each tablet containing 25 mg of Eltrombopag. It is important to use Revolade as prescribed and to follow the recommendations of healthcare professionals for optimal therapeutic outcomes.
Reviews
There are no reviews yet.